Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators
The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Abstract
Dysregulation of brain iron homeostasis is central to early neuropathological events in Alzhei mer's disease (AD), including oxidative stress, inflam matory processes, amyloid deposition, tau phosphory lation, and neuronal cell cycle regulatory failure, leading to apoptosis. Also, there is a direct link between iron metabolism and AD pathogenesis, demonstrated by the presence of an iron‐responsive element in the 5′ UTR of the amyloid precursor protein transcript. As a consequence of these findings, a new paradigm is emerging that includes the development of iron‐chelating neuroprotective‐neurorescue drugs with multimo dal functions, acting at various pathological brain tar gets. This concept is challenging the widely held assumption that “silver bullet” agents are superior to “dirty drugs” in drug therapy for neurodegenerative diseases. At best, the so‐called magic bullets exhibit moderate symptomatic activity without modifying the course of disease progression. The present review elaborates on conventional and novel therapeutic tar gets of various multifunctional iron‐chelating drugs ( e.g., chemically designed compounds; natural polyphe nols) that address multiple central nervous system etiologies in AD, aimed at preventing or slowing disease evolution. A similar approach in drug design is being investigated for treatment of cancer, AIDS, cardiovas cular diseases, and depression.—Amit, T., Avramovich‐Tirosh, Y., Youdim, M. B. H. Mandel, S. Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators. FASEB J . 22, 1296–1305 (2008)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The benefits of administration of desferrioxamine in Alzheimer’s, for instance, have been known for nearly 20 years (Crapper McLachlan et al. 1991), benefits since observed with other iron chelators”
Citations
Cites
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744 · cited 1×
“Both extracellular amyloid plaques and intracellular NFTs are central pathological hallmarks of AD (33).”
BackgroundYang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404751200 · Cited by 2,336
Iron, brain ageing and neurodegenerative disorders
Zecca, L., Youdim, M. B. H., Riederer, P., Connor, J. R., & Crichton, R. R. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1537 · Cited by 1,801
Self-citationCherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y.-S., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00317-8 · Cited by 1,447 · cited 1×
“burden and slowed the rate of cognitive decline (8).”
BackgroundMitochondrial abnormalities in Alzheimer's disease
Hirai, K., Aliev, G., Nunomura, A., Fujioka, H., Russell, R. L., Atwood, C. S., Johnson, A. B., Kress, Y., Vinters, H. V., Tabaton, M., et al. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-09-03017.2001 · Cited by 1,367 · cited 1×
“drial abnormalities (55); activation of select signal”
Iron accumulation in Alzheimer disease is a source of redox-generated free radicals
Smith, M. A., Harris, P. L. R., Sayre, L. M., & Perry, G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.18.9866 · Cited by 1,355
The metallobiology of Alzheimer's disease
Bush, A. I. (2003) · Trends in Neurosciences · doi:10.1016/s0166-2236(03)00067-5 · Cited by 1,315
Ritchie, C. W., Bush, A. I., Mackinnon, A., Macfarlane, S., Mastwyk, M., MacGregor, L., Kiers, L., Cherny, R., Li, Q.-X., Tammer, A., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1685 · Cited by 988 · cited 1×
“reduction in plasma amyloid-beta (A ) peptide A (1–42) and cognitive decline in AD patients (7), while in trans-”
BackgroundTargeting Multiple Signaling Pathways by Green Tea Polyphenol (−)-Epigallocatechin-3-Gallate
Khan, N., Afaq, F., Saleem, M., Ahmad, N., & Mukhtar, H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3636 · Cited by 820
Intramuscular desferrioxamine in patients with Alzheimer's disease
MCLACHLAN, D. (1991) · The Lancet · doi:10.1016/0140-6736(91)92978-b · Cited by 764
Cited by
Items 101–134 of 134
Khan, M. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115283 · Cited by 10
“The aggregation of the hyperphosphorylated tau protein caused by Fe3+ can be reversed by reducing Fe 3+ to Fe 2+ [98] and/or iron chelators [99].”
Tam, J. P., Huang, J., Loo, S., Li, Y.-M., & Kam, A. (2023) · Molecules · doi:10.3390/molecules28186556 · Cited by 6
Plant Polyphenols as Dietary Modulators of Brain Functions
Vauzour, D., Kerr, J. S., & Czank, C. (2013) · Polyphenols in Human Health and Disease · doi:10.1016/b978-0-12-398456-2.00027-x · Cited by 7
Neuroprotection induced by epigallocatechin-3-gallate
Tripathi, S., Mishra, R., Shrivastava, R., Srivastava, V. K., & Singh, G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23763-8.00029-4 · Cited by 8
Chimeric Conjugates for Alzheimer’s Disease
Dhala, I., Khan, T. A., & Prabhu, A. (2020) · Exon Publications eBooks · doi:10.36255/exonpublications.alzheimersdisease.2020.ch10 · Cited by 7
“High concentrations of Cu and Fe in the brain trigger the production of reactive oxygen species, which further exacerbates oxidative stress, thereby leading to worsening of AD (31, 32).”
BackgroundTargeting dysregulation of brain iron homeostasis in ageing
Weinreb, O., Amit, T., & Youdim, M. B. H. (2012) · Nutrition and Aging · doi:10.3233/nua-2012-0003 · Cited by 5
“[112] Amit T, Avramovich-Tirosh Y, Youdim MB, Mandel S.”
BackgroundSelf-citationNeuroprotective Effects of Polyphenols in Aging and Age‐Related Neurological Disorders
Corona, G., & Vauzour, D. (2017) · Wiley eBooks · doi:10.1002/9781119155195.ch3 · Cited by 5
Potential Neuroprotective Actions of Dietary Flavonoids
Vauzour, D., Rattray, M., Williams, R. J., & Spencer, J. P. E. (2013) · Springer eBooks · doi:10.1007/978-3-642-22144-6_71 · Cited by 4
“Alternatively, it is conceivable that EGCG reduces Ab plaque pathology by inhibiting amyloid aggregation and fibrillization either as a result of metal chelation activity [70–72] or by favoring the formation of nontoxic (off-target) oligomers [73].”
BackgroundKakhlon, O., Breuer, B., Münnich, A., & Cabantchik, Z. I. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-514-9_11 · Cited by 4
Zhang, Y., Zhao, J., Huang, T., Gao, X., Zhang, L., Wang, Y., Guo, X., Zhang, L., Niu, Q. L., & Zhang, Q. (2025) · Aquatic Toxicology · doi:10.1016/j.aquatox.2025.107479 · Cited by 3
Flavonoid-Based Derivatives for Modulating Various Targets of Alzheimer’s Disease
Pandey, J. (2023) · Springer eBooks · doi:10.1007/978-981-99-6038-5_11 · Cited by 4
Dysregulation of Neuronal Iron in Alzheimer’s Disease
Uddin, M. S., & Ashraf, G. M. (2021) · Current Neuropharmacology · doi:10.2174/1570159x20666211231163544 · Cited by 3
“Along with Aβ, iron can also bind with tau and can induce phosphorylation of tau, and phosphorylated tau aggregation, while this process can be reversed via iron chelators [43].”
BackgroundNeuropathology and Iron: Central Nervous System Iron Homeostasis
Texel, S. J., Xu, X., Pin, S., & Harris, Z. L. (2011) · Humana Press eBooks · doi:10.1007/978-1-60327-485-2_23 · Cited by 2
“One group has synthesized a range of novel chelators that are derivatives of the iron chelator VK-28 and are conjugated to the neuroprotective moiety of the drugs rasagiline and selegiline commonly used to treat Parkinson’s disease [ 62 ] .”
BackgroundNatural Chimeras of Existing Drugs for Alzheimer’s Disease: Expanding the Target Landscape
Dhala, I., Khan, T. A., & Prabhu, A. (2021) · Indian Journal of Pharmaceutical Education and Research · doi:10.5530/ijper.55.1s.35 · Cited by 3
Recent Advances in ALS Research: Perspectives for Personalized Clinical Application
Benkler, C., Offen, D., Melamed, E., Amit, T., Mandel, S. A., Youdim, M. B. H., & Weinreb, O. (2012) · Advances in predictive, preventive and personalised medicine · doi:10.1007/978-94-007-5866-7_11 · Cited by 1
“differentiation through various iron-associated biological events [57].”
Self-citationThe importance of the multiple target action of green tea polyphenols for neuroprotection
Silvia, A. M. (2011) · Frontiers in Bioscience-Scholar · doi:10.2741/286 · Cited by 1
Gal-Ben-Ari, S., & Youdim, M. B. H. (2022) · Springer eBooks · doi:10.1007/978-3-031-15080-7_211 · Cited by 1
Self-citationRadwan, A. A., Alanazi, F. K., & Rahman, A. M. A. (2024) · Preprints.org · doi:10.20944/preprints202402.0731.v1
Genetic Determinants of Cognitive Function and Age-Related Brain Changes
Schuur, M. (2010) · RePub (Erasmus University Rotterdam) · Cited by 1
Polyphénols et neuroprotection : où en sommes-nous aujourd’hui ?
Vauzour, D. (2014) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2014.01.001 · Cited by 1
Are Iron Chelators Safe to Be Used in Hyperoxia-induced Lung Injury?
Rezvani, N. (2011) · International Journal of Pharmacology · doi:10.3923/ijp.2011.546.547
Shallie, P. D., & Koya, K. (2017) · Journal of Advances in Medicine and Medical Research · doi:10.9734/bjmmr/2017/33329
“are: (i) anti-oxidant and anti-chelating activities; (ii) inhibition of ’S aggregation; and (iii) modulation of cell signalling pathways [26-28] Since iron burden and ROS are attributed to neuronal damage, iron chelation and antioxidative strategies are useful to protect neurodegeneration.”
BackgroundPolyphenols in neuroprotection and brain disorders
Duttaroy, A. K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822405-2.00004-9
Gal-Ben-Ari, S., & Youdim, M. B. H. (2021) · Springer eBooks · doi:10.1007/978-3-030-71519-9_211-1
Self-citationYoudim, M. B. H. (2015) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10221
Self-citation
Metadata
- Authors
- Amit, T., Avramovich‐Tirosh, Y., Youdim, M. B. H., & Mandel, S.
- Affiliations
- Technion – Israel Institute of Technology (IL)
- ORCID
- Youdim, Moussa B. H.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2007-11-29
- Volume
- 22
- Issue
- 5
- Pages
- 1296-1305
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2072788211
- Cited by
- 126
- References
- 89
- Citations by year
- 2025: 2 · 2024: 3 · 2023: 7 · 2022: 4 · 2021: 6 · 2020: 5 · 2019: 5 · 2018: 5 · 2017: 6 · 2016: 6 · 2015: 6 · 2014: 6 · 2013: 9 · 2012: 12
- FWCI
- 1.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The FASEB Journal (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Keywords
- Alzheimer's disease, iron chelators, brain iron homeostasis, neuroprotection, neurorestoration, oxidative stress, neuroinflammation, amyloid deposition, tau phosphorylation, neuronal apoptosis, iron-responsive element, amyloid precursor protein, polyphenols, disease-modifying therapy
- MeSH terms
- Alzheimer Disease, Animals, Brain, Catechin, Cell Cycle, Humans, Hydroxyquinolines, Iron, Iron Chelating Agents, Piperazines, Amyloid beta-Protein Precursor, PC12 Cells, Neuroprotective Agents, Neurodegenerative Diseases, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.